

STEMLINE THERAPEUTICS INC
Form 8-K
April 02, 2013

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of report (Date of earliest event reported): **April 1, 2013**

Stemline Therapeutics, Inc.

(Exact Name of Registrant as Specified in Charter)

Delaware
(State or Other Jurisdiction
of Incorporation)

001-35619
(Commission File Number)

45-0522567
(IRS Employer Identification
No.)

750 Lexington Avenue

New York, New York 10022

(Address of Principal Executive Offices)

Edgar Filing: STEMLINE THERAPEUTICS INC - Form 8-K

(646) 502-2310

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act.

 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act.

 - Pre-commencement communications pursuant to Rule 14d-2b under the Exchange Act.

 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
-

Item 2.02. Results of Operations and Financial Condition.

On April 1, 2013, Stemline Therapeutics Inc. (Stemline) issued a press release reporting its year end 2012 financial results. A copy of such press release is being furnished as Exhibit 99.1 to this report.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Stemline Therapeutics, Inc.
(Registrant)

Date: April 1, 2013

By: */s/ Ivan Bergstein*
Ivan Bergstein
Chairman, President and Chief Executive Officer

INDEX TO EXHIBITS

Exhibit Number	Description
99.1	Press Release dated April 1, 2013.